41 research outputs found
2010-2011 A Salute to Gershwin
https://spiral.lynn.edu/conservatory_philharmonia/1101/thumbnail.jp
Phase 1b/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma
PURPOSE: To assess the safety of the superoxide dismutase mimetic GC4419 in combination with radiation and concurrent cisplatin for patients with oral cavity or oropharyngeal cancer (OCC) and to assess the potential of GC4419 to reduce severe oral mucositis (OM).
PATIENTS AND METHODS: Patients with locally advanced OCC treated with definitive or postoperative intensity modulated radiation therapy (IMRT) plus cisplatin received GC4419 by 60-minute intravenous infusion, ending \u3c60 minutes before IMRT, Monday through Friday for 3 to 7 weeks, in a dose and duration escalation study. Oral mucositis was assessed twice weekly during and weekly after IMRT.
RESULTS: A total of 46 patients received GC4419 in 11 separate dosing and duration cohorts: dose escalation occurred in 5 cohorts receiving 15 to 112 mg/d over 3 weeks (n=20), duration escalation in 3 cohorts receiving 112 mg/d over 4 to 6 weeks (n=12), and then 3 additional cohorts receiving 30 or 90 mg/d over 6 to 7 weeks (n=14). A maximum tolerated dose was not reached. One dose-limiting toxicity (grade 3 gastroenteritis and vomiting with hyponatremia) occurred in each of 2 separate cohorts at 112 mg. Nausea/vomiting and facial paresthesia during infusion seemed to be GC4419 dose-related. Severe OM occurred through 60 Gy in 4 of 14 patients (29%) dosed for 6 to 7 weeks, with median duration of only 2.5 days.
CONCLUSIONS: The safety of GC4419 concurrently with chemoradiation for OCC was acceptable. Toxicities included nausea/vomiting and paresthesia. Doses of 30 and 90 mg/d administered for 7 weeks were selected for further study. In an exploratory analysis, severe OM seemed less frequent and briefer than expected
Decoding the Molecular Universe -- Workshop Report
On August 9-10, 2023, a workshop was convened at the Pacific Northwest
National Laboratory (PNNL) in Richland, WA that brought together a group of
internationally recognized experts in metabolomics, natural products discovery,
chemical ecology, chemical and biological threat assessment, cheminformatics,
computational chemistry, cloud computing, artificial intelligence, and novel
technology development. These experts were invited to assess the value and
feasibility of a grand-scale project to create new technologies that would
allow the identification and quantification of all small molecules, or to
decode the molecular universe. The Decoding the Molecular Universe project
would extend and complement the success of the Human Genome Project by
developing new capabilities and technologies to measure small molecules
(defined as non-protein, non-polymer molecules less than 1500 Daltons) of any
origin and generated in biological systems or produced abiotically. Workshop
attendees 1) explored what new understanding of biological and environmental
systems could be revealed through the lens of small molecules; 2) characterized
the similarities in current needs and technical challenges between each science
or mission area for unambiguous and comprehensive determination of the
composition and quantities of small molecules of any sample; 3) determined the
extent to which technologies or methods currently exist for unambiguously and
comprehensively determining the small molecule composition of any sample and in
a reasonable time; and 4) identified the attributes of the ideal technology or
approach for universal small molecule measurement and identification. The
workshop concluded with a discussion of how a project of this scale could be
undertaken, possible thrusts for the project, early proof-of-principle
applications, and similar efforts upon which the project could be modeled
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication
Experimental Study of Tire Inner Liner
Cracks were observed in field tested tire inner liners. When two versions of the material were studied with specialized Adkins Creep Fixtures, it was found that cracks developed parallel to the loading direction in samples tested at cold temperatures (-40 C in this study). Also, an experimental Arcan fixture was used in conjunction with digital image correlation to learn the full-field strain state of the inner liner material under simulated loading conditions. It was found that the effective strain directions correspond to those of observed cracks in field testing, and that local thickness variations, defects (like voids), surface geometry and anisotropy may be exaggerating the effects of applied loads